Cellular strategies for accommodating replication-hindering adducts in DNA: control by the SOS response in Escherichia coli.
The replication of double-stranded plasmids containing a single adduct was analyzed in vivo by means of a sequence heterology that marks the two DNA strands. The single adduct was located within the sequence heterology, making it possible to distinguish trans-lesion synthesis (TLS) events from damage avoidance events in which replication did not proceed through the lesion. When the SOS system of the host bacteria is not induced, the C8-guanine adduct formed by the carcinogen N-2-acetylaminofluorene (AAF) yields less than 1% of TLS events, showing that replication does not readily proceed through the lesion. In contrast, the deacetylated adduct N-(deoxyguanosin-8-yl)-2-aminofluorene yields approximately 70% of TLS events under both SOS-induced and uninduced conditions. These results for TLS in vivo are in good agreement with the observation that AAF blocks DNA replication in vitro, whereas aminofluorene does so only weakly. Induction of the SOS response causes an increase in TLS events through the AAF adduct (approximately 13%). The increase in TLS is accompanied by a proportional increase in the frequency of AAF-induced frameshift mutations. However, the polymerase frameshift error rate per TLS event was essentially constant throughout the SOS response. In an SOS-induced delta umuD/C strain, both US events and mutagenesis are totally abolished even though there is no decrease in plasmid survival. Error-free replication evidently proceeds efficiently by means of the damage avoidance pathway. We conclude that SOS mutagenesis results from increased TLS rather than from an increased frameshift error rate of the polymerase.
Koffel-Schwartz
N
N
Cancérogenèse et Mutagenèse Moléculaire et Structurale, Unité Propre de Recherche (no. 9003) du Centre National de la Recherche Scientifique ESBS, Strasbourg, France.
Coin
F
F
Veaute
X
X
Fuchs
R P
RP
D015073:2-Acetylaminofluorene / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000494:pharmacology; D001483:Base Sequence; D002273:Carcinogens / Q000378:metabolism* / Q000494:pharmacology; D018736:DNA Adducts / Q000378:metabolism*; D004249:DNA Damage; D004261:DNA Replication; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics* / Q000502:physiology; D005449:Fluorenes / Q000378:metabolism* / Q000494:pharmacology; D006147:Guanine; D008969:Molecular Sequence Data; D016296:Mutagenesis; D015345:Oligonucleotide Probes; D015183:Restriction Mapping; D013014:SOS Response, Genetics; D014466:Ultraviolet Rays
D002273:Carcinogens; D018736:DNA Adducts; D005449:Fluorenes; D015345:Oligonucleotide Probes; C031838:N-(deoxyguanosin-8-yl)-2-aminofluorene; C018776:N-(deoxyguanosin-8-yl)acetylaminofluorene; D006147:Guanine; D015073:2-Acetylaminofluorene; D003849:Deoxyguanosine